CL2021003026A1 - Formulaciones estabilizadas que contienen anticuerpos anti-angptl3. - Google Patents
Formulaciones estabilizadas que contienen anticuerpos anti-angptl3.Info
- Publication number
- CL2021003026A1 CL2021003026A1 CL2021003026A CL2021003026A CL2021003026A1 CL 2021003026 A1 CL2021003026 A1 CL 2021003026A1 CL 2021003026 A CL2021003026 A CL 2021003026A CL 2021003026 A CL2021003026 A CL 2021003026A CL 2021003026 A1 CL2021003026 A1 CL 2021003026A1
- Authority
- CL
- Chile
- Prior art keywords
- angptl3
- formulations containing
- antibody
- containing anti
- stabilized formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852643P | 2019-05-24 | 2019-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003026A1 true CL2021003026A1 (es) | 2022-06-24 |
Family
ID=72179136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003026A CL2021003026A1 (es) | 2019-05-24 | 2021-11-16 | Formulaciones estabilizadas que contienen anticuerpos anti-angptl3. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12559551B2 (https=) |
| EP (1) | EP3976647A1 (https=) |
| JP (1) | JP7783051B2 (https=) |
| KR (1) | KR20220011727A (https=) |
| CN (1) | CN114007647A (https=) |
| AU (1) | AU2020282956A1 (https=) |
| BR (1) | BR112021023501A2 (https=) |
| CA (1) | CA3139333A1 (https=) |
| CL (1) | CL2021003026A1 (https=) |
| CO (1) | CO2021016183A2 (https=) |
| EA (1) | EA202193240A1 (https=) |
| IL (1) | IL288153A (https=) |
| MA (1) | MA56049A (https=) |
| MX (1) | MX2021014332A (https=) |
| PH (1) | PH12021552788A1 (https=) |
| SG (1) | SG11202112256SA (https=) |
| WO (1) | WO2020243031A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| CN107635527B (zh) | 2015-03-10 | 2021-04-23 | 里珍纳龙药品有限公司 | 无菌刺穿系统和方法 |
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| KR102540409B1 (ko) | 2017-05-05 | 2023-06-09 | 리제너론 파아마슈티컬스, 인크. | 자동 주사기 |
| WO2022191550A1 (ko) * | 2021-03-09 | 2022-09-15 | (주)지아이이노베이션 | ＩｇＥ Ｆｃ 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형 |
| TW202320847A (zh) * | 2021-07-21 | 2023-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種抗ａｎｇｐｔｌ３抗體或其抗原結合片段的醫藥組成物及其用途 |
| USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
| IL313191A (en) | 2021-12-22 | 2024-07-01 | Regeneron Pharma | Treatment of kidney diseases using angiopoietin-like inhibitors 3 |
| WO2023213779A1 (en) | 2022-05-02 | 2023-11-09 | Novo Nordisk A/S | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration |
| JP2025537256A (ja) | 2022-11-10 | 2025-11-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンジオポエチン様３（ａｎｇｐｔｌ３）阻害剤と溶質担体ファミリー５メンバー２（ｓｌｃ５ａ２）阻害剤の組み合わせによる腎疾患の治療 |
| TW202529831A (zh) | 2023-10-02 | 2025-08-01 | 美商再生元醫藥公司 | 藥物遞輸裝置安全系統 |
| WO2026051789A1 (zh) * | 2024-09-03 | 2026-03-12 | 四川科伦博泰生物医药股份有限公司 | Pcsk9和angptl3的结合蛋白及其用途 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US20020035058A1 (en) | 1996-05-15 | 2002-03-21 | The University Of Sheffield | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| US6172071B1 (en) | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| AU781295B2 (en) | 1999-02-12 | 2005-05-12 | President And Fellows Of Harvard College | Inhibiting formation of atherosclerotic lesions |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| NZ527408A (en) | 2001-02-22 | 2005-04-29 | Skyepharma Canada Inc | Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia |
| JP5105696B2 (ja) | 2001-11-16 | 2012-12-26 | ジェネンテック， インコーポレイテッド | アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法 |
| US20070185017A1 (en) | 2002-10-29 | 2007-08-09 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2005080508A (ja) | 2003-09-04 | 2005-03-31 | Sankyo Co Ltd | 脂質代謝改善剤の試験方法 |
| AU2006223579A1 (en) | 2005-03-11 | 2006-09-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| PL2121751T3 (pl) | 2006-12-08 | 2017-07-31 | Lexicon Pharmaceuticals, Inc. | Przeciwciała monoklonalne przeciwko ANGPTL3 |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| JP5711671B2 (ja) | 2009-02-23 | 2015-05-07 | ナノルクス、インコーポレイテッドＮａｎｏｒｘ，Ｉｎｃ． | ポリコサノールナノ粒子 |
| CN101852805B (zh) | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
| AU2010273570B2 (en) | 2009-07-14 | 2014-07-03 | Novartis Ag | Mesenchymal stem cell differentiation |
| US8653047B2 (en) | 2010-01-08 | 2014-02-18 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| ES2923573T3 (es) | 2011-06-21 | 2022-09-28 | Alnylam Pharmaceuticals Inc | Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas |
| US9574005B2 (en) | 2011-07-19 | 2017-02-21 | Chugai Seiyaku Kabushiki Kaisha | Stable Protein-containing preparation containing argininamide or analogous compound thereof |
| US20150239970A1 (en) | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| EP2996706B1 (en) | 2013-03-14 | 2019-07-31 | UAB Research Foundation | Apolipoprotein mimetics and uses thereof |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW202021614A (zh) | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| HK1224186A1 (zh) | 2013-11-20 | 2017-08-18 | Cymabay Therapeutics, Inc. | 纯阖家族型高胆固醇血症的治疗 |
| CN111394355A (zh) | 2013-12-24 | 2020-07-10 | Ionis制药公司 | 促血管生成素样3表达的调节 |
| PT3137605T (pt) | 2014-05-01 | 2020-12-18 | Ionis Pharmaceuticals Inc | Composições e métodos para modulação da expressão de angiopoietina de tipo 3 |
| RU2723018C2 (ru) | 2014-07-16 | 2020-06-08 | Санофи Байотекнолоджи | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию |
| PL3169353T3 (pl) | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
| EP3822287A1 (en) | 2014-10-03 | 2021-05-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| PL3416684T3 (pl) | 2016-02-17 | 2023-11-06 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia lub profilaktyki miażdżycy tętnic przez podawanie inhibitora angptl3 |
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| KR20180132843A (ko) | 2016-04-08 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법 |
| IL293308B2 (en) | 2016-04-28 | 2024-12-01 | Regeneron Pharma | Methods for treating patients with familial hypercholesterolemia |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| AU2021320417A1 (en) | 2020-08-07 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating refractory hypercholesterolemia involving an ANGPTL3 inhibitor |
-
2020
- 2020-05-22 US US16/882,280 patent/US12559551B2/en active Active
- 2020-05-24 BR BR112021023501A patent/BR112021023501A2/pt unknown
- 2020-05-24 WO PCT/US2020/034438 patent/WO2020243031A1/en not_active Ceased
- 2020-05-24 PH PH1/2021/552788A patent/PH12021552788A1/en unknown
- 2020-05-24 SG SG11202112256SA patent/SG11202112256SA/en unknown
- 2020-05-24 CN CN202080046178.3A patent/CN114007647A/zh active Pending
- 2020-05-24 MX MX2021014332A patent/MX2021014332A/es unknown
- 2020-05-24 CA CA3139333A patent/CA3139333A1/en active Pending
- 2020-05-24 EA EA202193240A patent/EA202193240A1/ru unknown
- 2020-05-24 JP JP2021569354A patent/JP7783051B2/ja active Active
- 2020-05-24 MA MA056049A patent/MA56049A/fr unknown
- 2020-05-24 EP EP20760579.1A patent/EP3976647A1/en active Pending
- 2020-05-24 AU AU2020282956A patent/AU2020282956A1/en active Pending
- 2020-05-24 KR KR1020217042347A patent/KR20220011727A/ko not_active Ceased
-
2021
- 2021-11-16 CL CL2021003026A patent/CL2021003026A1/es unknown
- 2021-11-16 IL IL288153A patent/IL288153A/en unknown
- 2021-11-29 CO CONC2021/0016183A patent/CO2021016183A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021014332A (es) | 2022-04-06 |
| MA56049A (fr) | 2022-04-06 |
| CO2021016183A2 (es) | 2021-12-10 |
| EA202193240A1 (ru) | 2022-03-14 |
| JP7783051B2 (ja) | 2025-12-09 |
| IL288153A (en) | 2022-01-01 |
| KR20220011727A (ko) | 2022-01-28 |
| JP2022532927A (ja) | 2022-07-20 |
| PH12021552788A1 (en) | 2022-09-28 |
| CN114007647A (zh) | 2022-02-01 |
| CA3139333A1 (en) | 2020-12-03 |
| EP3976647A1 (en) | 2022-04-06 |
| US20200369760A1 (en) | 2020-11-26 |
| BR112021023501A2 (pt) | 2022-01-18 |
| WO2020243031A1 (en) | 2020-12-03 |
| AU2020282956A1 (en) | 2022-01-27 |
| SG11202112256SA (en) | 2021-12-30 |
| US12559551B2 (en) | 2026-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021016183A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-angptl3 | |
| CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
| Oller‐Salvia et al. | MiniAp‐4: a venom‐inspired peptidomimetic for brain delivery | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| PE20050394A1 (es) | FORMULACIONES DE ANTICUERPO MONOCLONAL anti-lge ALTAMENTE CONCENTRADO | |
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| UY33515A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ngf | |
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| NZ711567A (en) | Antibody formulations | |
| EA201790989A1 (ru) | Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации | |
| HRP20201268T1 (hr) | Stabilne formulacije koje sadrže anti-pcsk9 antitijela | |
| HRP20250628T1 (hr) | Mješavine antitijela i postupci njihove upotrebe | |
| BR112012022223A2 (pt) | formulações de proteína concentrada e usos das mesmas | |
| MX2011011772A (es) | Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina. | |
| HRP20211660T1 (hr) | Postupci i pripravci za dostavu aril-sulfataze-a u središnji živčani sustav | |
| CO2021011648A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33 | |
| EA031209B9 (ru) | Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения | |
| ECSP12012092A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| HRP20230387T1 (hr) | Farmaceutski pripravci koji sadrže anti-beta amiloidna antitijela | |
| CR20210318A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| DE60333821D1 (de) | Stabilisierte albumin-zubereitungen | |
| JP2020531523A5 (https=) | ||
| WO2024254281A3 (en) | Compositions of conjugated and unconjugated proteins | |
| BR112022010488A2 (pt) | Formulação farmacêutica, uso da formulação farmacêutica, e, método para tratamento de um paciente | |
| CL2022003586A1 (es) | Formulaciones de anticuerpo de activina a y métodos para utilizarlas |